Iron Deficiency Anemia

Iron-deficiency anemia is the most prevalent type of anemia which occurs due to the lack of iron in the body. Protheragen advances preclinical drug development by sophisticated therapy design and model system engineering based on modern concepts of the pathogenesis of iron-deficiency anemia. We strive to provide the most thorough assistance possible to make the process of developing a drug easier.

Overview of Iron-Deficiency Anemia

Iron-deficiency anemia is the most common disorder related to nutrition, with approximately 1.2 billion people affected, particularly women of reproductive age and children under 5 in developing regions. Iron-deficiency anemia arises from an imbalance between iron loss, physiological demand, dietary intake, resulting in decreased hemoglobin synthesis and microcytic, hypochromic erythrocytes.

Fig.1 Overview of the biological consequences of iron deficiency. (Alnuwaysir R I S, et al., 2021)

Pathogenesis of Iron-Deficiency Anemia

Iron-deficiency anemia develops when the body is low on available iron stores, resulting in low hemoglobin and red blood cell production. This can occur from inadequate dietary iron intake, iron absorption difficulties, chronic blood loss, high iron needs, or some conditions which impact the iron metabolism in the body. The absence of iron makes it impossible for the body to make hemoglobin leading to pallor of skin, weakness, fatigue and breathlessness.

Fig.2 Pathogenesis of iron-deficiency anemia and methods for supplementation and treatment in inflammatory bowel disease (IBD). (Nielsen O H, et al., 2018)

Therapy Development for Iron-Deficiency Anemia

Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.

Our Services

Protheragen is committed to delivering unparalleled diagnostic and therapeutic development services tailored specifically for iron-deficiency anemia. Our expertise extends to the development of cutting-edge disease models that drive preclinical studies into potential therapies. With a focus on innovation and precision, we empower our clients with advanced solutions that pave the way for effective intervention strategies.

Therapeutic Development

• Small Molecule Drug Development
• Cell Therapy Development
• Gene Therapy Development
• Therapeutic Antibody Development
• Therapeutic Peptide Development
• Therapeutic Protein Development

Animal Model Development

• Induced Model: Iron-deficiency anemia (IDA) is induced in experimental animals by feeding them defined diets with low iron content.
• Slc11a2 Knockout Model: Our scientists generated systemic and intestinal-specific Slc11a2 KO mice, both of which displayed severe systemic iron deficiency and IDA.

Committed to fostering innovation, Protheragen specializes in supporting the development of innovative therapeutics through comprehensive preclinical research services, including pharmacodynamics (PD), pharmacokinetic (PK) and toxicology studies. Our customized approach addresses the unique challenges of your studies and helps you optimize your drug candidates for commercial success. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.

References

• Alnuwaysir R I S, Hoes M F, van Veldhuisen D J, et al. Iron deficiency in heart failure: mechanisms and pathophysiology[J]. Journal of clinical medicine, 2021, 11(1): 125.
• Nielsen O H, Soendergaard C, Vikner M E, et al. Rational management of iron-deficiency anemia in inflammatory bowel disease[J]. Nutrients, 2018, 10(1): 82.